Investigators at Complutense University in Madrid assessed the impact of WIN55,512-2, a synthetic cannabinoid agonist, in an animal model of multiple sclerosis (MS).
Researchers reported that the treatment moderated disease progression and reduced MS symptom, including spasms and tremors.
"In summary, the treatment of EAE (experimental autoimmune encephalomyelitis) mice with the cannabinoid agonist WIN55,512-2 reduced their neurological disability and the progression of the disease," authors concluded. "This effect was exerted through the activation of CB(1) receptors, which would exert a positive influence in the reduction of inflammatory events linked to the pathogenesis of this disease."...Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1815